Enterprise Products Partners delivered record results for full-year 2025, reporting consolidated adjusted EBITDA of $8.3 billion and record total volumes of 11.2 million barrels per day equivalent. The master limited partnership increased its total cash distributions by 3.8%, marking the 27th consecutive annual boost. Coverage remains conservative at 1.7 times the quarterly payout, supporting a 6.7% distribution yield. Free cash flow reached $4.1 billion, strengthening the partnership’s liquidity position and underpinning its long-standing commitment to reliable income for unitholders.

Management has outlined a targeted growth capital expenditure of $2.5–2.9 billion for 2026, with key projects including the $450 million Bahia Pipeline expansion from Corpus Christi to the U.S. Gulf Coast export terminals, additional fractionation capacity in the Mont Belvieu complex and incremental storage assets in Houston. These projects are expected to add 120,000 barrels per day of NGL handling and contribute approximately $250 million in annual EBITDA upon full commissioning. Enterprise’s backlog of sanctioned projects stands at $3.7 billion, with a further $1.2 billion of high-return opportunities under advanced evaluation.

Institutional repositioning included Principal Financial reducing its stake by 17.9%, selling roughly 1.03 million common units for proceeds near $147 million; total institutional ownership remains at 73.9%. In late 2025, the board approved a $5.0 billion share repurchase program, authorizing repurchases of up to 7.4% of outstanding units, signaling management’s view of current valuation. As of year-end, Enterprise maintained a debt-to-equity ratio of 1.04, a current ratio of 0.88 and a quick ratio of 0.60. The partnership’s net leverage sits at 3.5 times net debt to adjusted EBITDA, consistent with its investment-grade credit metrics.

Analyst firms continue to favor Enterprise’s midstream franchise, with eight Buy ratings, one Strong Buy, five Hold and two Sell recommendations. Citigroup reiterated a Buy rating raising its target to $36.00, Raymond James converted its Strong Buy to Outperform at a $36.00 objective, while JPMorgan maintained Neutral at $35.00. Wolfe Research stands out as the sole Underperform, assigning a $31.00 price target. The consensus target among the 16 analysts tracked is $34.77, reflecting moderate upside potential of roughly 5% from current levels based on peer-adjusted distributable cash flow multiples.